PPIDT00399
Drug Information
| Name | Risankizumab |
|---|---|
| Sequence | QVQLVQSGAEVKKPGSSVKVSCKASGYTFTDQTIHWMRQAPGQGLEWIGYIYPRDDSPKYNENFKGKVTITADKSTSTAYMELSSLRSEDTAVYYCAIPDRSGYAWFIYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG |
| DrugBank_ID | DB14762 |
| Type | biotech |
| Indication | Risankizumab is indicated to treat: - moderate-to-severe **plaque psoriasis** in adults who are candidates for systemic therapy or phototherapy.[L39885,L44191,L44231] - active **psoriatic arthritis** in adults.[L39885,L44191,L44231] In Canada and Europe, it may be used alone or in combination with a conventional non-biologic disease-modifying antirheumatic drug (cDMARD) (e.g., methotrexate).[L44191,L44231] - moderately to severely active **Crohn's disease** in adults.[L39885,L44191,L44231] In Canada, it is used in patients who have had an inadequate response, intolerance, or demonstrated dependence on corticosteroids; or an inadequate response, intolerance, or loss of response to immunomodulators or biologic therapies.[L44191] - moderately to severely active **ulcerative colitis** in adults.[L50938] |
Dosage Forms
| Form | Route | Strength |
|---|---|---|
| Injection | Intravenous |
60 mg/1mL
|
| Injection | Subcutaneous |
150 mg/1mL
|
| Injection, solution | Parenteral; Subcutaneous |
150 MG
|
| Injection, solution | Parenteral; Subcutaneous |
360 mg
|
| Injection, solution | Parenteral; Subcutaneous |
75 MG
|
| Injection, solution | Parenteral; Subcutaneous |
90 mg
|
| Injection, solution | Subcutaneous |
360 mg
|
| Injection, solution | Subcutaneous |
90 mg
|
| Injection, solution, concentrate | Intravenous |
600 mg
|
| Injection, solution; kit | Subcutaneous |
90 mg/1mL
|
| Injection, solution; kit | Subcutaneous; Topical |
|
| Kit | Intravenous |
180 mg/1.2mL
|
| Kit | Intravenous |
360 mg/2.4mL
|
| Solution | Intravenous |
60 mg / mL
|
| Solution | Subcutaneous |
150 mg / 1 mL
|
| Solution | Subcutaneous |
180 mg / 1.2 mL
|
| Solution | Subcutaneous |
360 mg / 2.4 mL
|
| Solution | Subcutaneous |
75 mg / 0.83 mL
|
| Solution | Subcutaneous |
75.000 mg
|
| Solution | Subcutaneous |
90 mg / 1 mL
|
| Injection, solution | — |
150 mg/ml
|
| Injection, solution | Subcutaneous |
75 mg
|
| Injection, solution | Subcutaneous |
150 mg
|
| Solution | — |
150 MG/ML
|
| Injection, solution | Subcutaneous |
150 mg/mL
|
| Injection, solution | Subcutaneous |
75 mg/0.83mL
|